Reuters: Health
A British baby's death this year after getting Novartis's gene therapy Zolgensma was not caused by a toxic drug reaction, the Swiss drugmaker said, allaying concerns over the $2.1 million-per-patient treatment's risks.
British baby's death not due to SMA gene therapy: Novartis
British baby's death not due to SMA gene therapy: Novartis
Reuters: Health
A British baby's death this year after getting Novartis's gene therapy Zolgensma was not caused by a toxic drug reaction, the Swiss drugmaker said, allaying concerns over the $2.1 million-per-patient treatment's risks.
Reuters: Health
A British baby's death this year after getting Novartis's gene therapy Zolgensma was not caused by a toxic drug reaction, the Swiss drugmaker said, allaying concerns over the $2.1 million-per-patient treatment's risks.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment